FDA Approves Cosibelimab for Advanced Skin Cancer
Checkpoint Therapeutics’ cosibelimab has received FDA approval for treating metastatic and locally advanced cutaneous squamous cell carcinoma (CSCC). The PD-L1 inhibitor is available under the brand name Unloxcyt, which was approved for use in CSCC patients with no curable options through surgery or radiation. According to a study, cosibelimab showed promising results, achieving a 47% … Read more